Get App
Download App Scanner
Scan to Download
Advertisement

Divi's Labs Delivers A Strong Q1, But Systematix Sees Limited Upside Ahead — Here's Why

Divi's reiterated its confidence in sustaining double-digit revenue growth over the medium term, supported by commercialisation of validation projects, peptide opportunities, ongoing capacity additions and continued momentum in the custom synthesis business, adds Systematix.

Divi's Labs Delivers A Strong Q1, But Systematix Sees Limited Upside Ahead — Here's Why
Divi's Labs revenue of Rs 30,800 million grew 28% YoY, significantly ahead of Systematix' estimate by 11% and consensus expectations by 12%.
(Photo: NDTV Profit/ AI generated image)
STOCKS IN THIS STORY
Divis Laboratories Ltd.
--

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Systematix Report

The brokerage firm Systematix has made a modest changes to its earnings estimates to factor in Divi's Laboratories Ltd.'s Q1 performance. However, the brokerage has maintained its Hold rating with a target price of Rs 7,959 (50 times FY28E earnings per share) as the sharp run-up in the stock largely reflects the improving business outlook, limiting meaningful upside from current levels.

The brokerage estimate FY26-28E revenue/Ebitda/EPS CAGR of 19%/31%/32% respectively.

Divi's Laboratories revenue of Rs 30,800 million grew 28% YoY, significantly ahead of the brokerage's estimate by 11% and consensus expectations by 12%.

The beat was primarily driven by the Custom Synthesis (CCS) business, which grew 46% YoY versus our expectation of 20%, aided by robust execution across commercial molecules, higher contribution from commercial manufacturing programs and a favourable product mix.

The Generics business (10% YoY vs estimate of 12%) marginally underperformed due to continued pricing pressure, while Nutraceuticals (19% YoY vs 10% estimate) delivered a stronger-than-expected performance, supported by healthy global demand and continued portfolio expansion.

Click on the attachment to read the full report:

Systematix Divis Q1 Review.pdf
VIEW DOCUMENT

ALSO READ: Sun Pharma Shares In Focus As Motilal Oswal Remains Bullish After Q1 Results — Check Hiked Target Price

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

 

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Loading PDF...
Listen to the latest songs, only on JioSaavn.com